OncoMatch/Clinical Trials/NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Is NCT06952504 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for endometrial cancer.
Treatment: Pembrolizumab · Carboplatin · Paclitaxel · Docetaxel · Sacituzumab Tirumotecan — Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage III, IV
measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per RECIST 1.1
Prior therapy
Must have received: platinum-based chemotherapy — adjuvant and/or neoadjuvant, curative-intent
1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent
Must have received: radiation therapy
prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of induction treatment
Must have received: hormonal therapy
prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment
Cannot have received: anti-PD-1 therapy
prior therapy in any setting with any of the following: anti-programmed cell death 1 protein
Cannot have received: anti-PD-L1 therapy
prior therapy in any setting with any of the following: anti-programmed cell death ligand 1
Cannot have received: anti-PD-L2 therapy
prior therapy in any setting with any of the following: anti-programmed cell death ligand 2 agent
Cannot have received: checkpoint inhibitor
agent directed to another stimulatory or coinhibitory T-cell receptor
Cannot have received: antibody-drug conjugate
trophoblast cell surface antigen 2-targeted antibody drug conjugate
Cannot have received: antibody-drug conjugate
topoisomerase I inhibitor-containing antibody drug conjugate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of South Alabama, Mitchell Cancer Institute ( Site 6033) · Mobile, Alabama
- Alaska Women's Cancer Care ( Site 6036) · Anchorage, Alaska
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) · Orange, California
- John Muir Health Cancer Center ( Site 6028) · Walnut Creek, California
- Yale University School of Medicine ( Site 6009) · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify